Search clinical trials for: Interleukin-2

Total 16580 results

Tanta University

Completed

IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients

Covid19

Egypt
Assistance Publique - Hôpitaux de Paris

Completed

Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes (DFIL2-Child)

Type 1 Diabetes

France
University Hospital, Bordeaux

Completed

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (ANEMIL)

Autoimmune Hemolytic Anemia

France
University of Michigan Rogel Cancer Center
University of Michigan

Terminated

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

Metastatic Colorectal Cancer

United States
Loma Linda University

Withdrawn

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Melanoma | Metastatic Kidney Cancer

United States
Weill Medical College of Cornell University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Hepatitis C

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose Interleukin-2 in Women With Unexplained Miscarriages (FaCIL-2)

Recurrent Miscarriage

France
City of Hope Medical Center

Completed

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Glioblastoma | Brain Tumor | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Anaplastic Meningioma | Mixed Glioma | Brain Stem Glioma | Ependymoblastoma | Grade III Meningioma | Meningeal Hemangiopericytoma | Pineal Gland Astrocytoma

United States
French National Agency for Research on AIDS and...
Chiron Corporation

Completed

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

HIV Infections

France
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Ultra Low Dose Interleukin-2 in Healthy Volunteers

Hematologic Diseases

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Peking University Cancer Hospital & Institute

Completed

Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion (GMPE)

Breast Neoplasms | Neoplasm Metastasis | Immunotherapy | Gene Expression Profiling

China
Icahn School of Medicine at Mount Sinai

Completed

Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency

Common Variable Immunodeficiency
Aalborg University Hospital

Unknown

Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)

HIV Infections | Hepatitis B | Hepatitis A

Denmark
Astellas Pharma Global Development, Inc.

Completed

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (PILOT)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Germany, Latvia
King's College London
King's College Hospital NHS Trust

Terminated

Low-dose IL-2 for Treg Expansion and Tolerance (LITE) (LITE)

Liver Diseases | Transplantation

United Kingdom
Vical
National Cancer Institute (NCI); Jonsson Comprehensive Cancer Center

Terminated

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Lava Therapeutics

Active, not recruiting

Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Lymphocytic Leukemia

United States, Spain, France, Netherlands
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States
Rockefeller University

Completed

Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

HIV Infections

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Radboud University Medical Center

Unknown

The Effect of Anakinra on Insulin Secretion

Glucose Intolerance | Diabetes Mellitus Type 2 | Impaired Insulin Secretion

Netherlands
Masonic Cancer Center, University of Minnesota

Withdrawn

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Pulmonary Metastases | Metastatic Melanoma | Brain Metastases | Hepatic Metastases

United States
Vical
National Cancer Institute (NCI); Jonsson Comprehensive Cancer Center

Terminated

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

Prostate Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Locally Advanced Rectal Adenocarcinoma

China
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases (TRANSREG)

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Psoriasis | Systemic Sclerosis | Crohn's Disease | Ulcerative Colitis | Idiopathic Thrombocytopenic Purpura | Autoimmune Hepatitis | Wegener's Granulomatosis | Ankylosing Spondylitis | Behcet's Disease | Takayasu's Disease | Sclerosing Cholangitis | Gougerot-sj...

France
Cambridge University Hospitals NHS Foundation Trust

Not yet recruiting

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution. (ELLIPSE)

Carotid Artery Plaque | Carotid Atherosclerosis | TIA

United Kingdom
Bayer

Completed

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

HIV Infections

France, United States, United Kingdom
Liu Tian

Recruiting

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

High Risk Non-Hodgkin's Lymphoma

United States
Ahmad Tarhini
Prometheus Laboratories

Terminated

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Second Xiangya Hospital of Central South University

Not yet recruiting

Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

China
University of Washington
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Beijing Tongren Hospital

Completed

A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis (MERAK)

Allergic Rhinitis

China
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | EBV-Positive Neoplastic Cells Present | HLA-A*0201 Positive Cells Present | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Elevated WT1

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH); Chiron...

Completed

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Kidney Cancer

United States
National Human Genome Research Institute (NHGRI)

Completed

Twins Study of Gene Therapy for HIV Infection

Acquired Immunodeficiency Syndrome | HIV Infection | Kaposi's Sarcoma

United States
Peking University People's Hospital

Recruiting

Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
National Institute of Allergy and Infectious Diseases...
Chiron Corporation

Completed

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (ESPRIT)

HIV Infections

United States, Brazil, Australia, Argentina, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Morocco, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, Thailand, United Kingdom
Providence Health & Services
Prometheus Laboratories

Active, not recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. (SBRT/IL-2)

Metastatic Melanoma

United States
Sohag University

Not yet recruiting

Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo

Vitiligo
University of Washington
National Cancer Institute (NCI)

Completed

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Gregory Knapp

Not yet recruiting

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Triple Negative Breast Cancer

Search clinical trials for: Interleukin-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations